Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - Cerylid
Alternative Names: CBL 1155; CBL 1309; KN 309Latest Information Update: 07 Feb 2011
Price :
$50
*
At a glance
- Originator Cerylid Biosciences
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Thrombosis
Most Recent Events
- 15 Jun 2005 Compounds from this programme are available for licensing (http://www.cerylid.com.au)
- 17 May 2005 Preclinical trials in Thrombosis in Australia (PO)
- 17 May 2005 Preclinical trials in Cancer in Australia (unspecified route)